Authors


Kevin Brigle, PhD

Latest:

Future of R/R MM: Emerging Agents

In this segment, Dr Mohan asks Dr Mann about emerging investigational agents for the management of relapsed/refractory multiple myeloma (R/R MM) that show particular promise.



Cao Yi-Wei, MM

Latest:

Extranodal NK/T-Cell Lymphoma Misdiagnosed as Pulmonary Infection

This case report explores the diagnosis and treatment of extranodal NK/T-cell lymphoma, highlighting clinical challenges and advancements in pathology and therapy.


Maya Guhan, BA

Latest:

Unusual Initial Presentation of Hepatocellular Carcinoma as a Clavicular Head Mass

Rohit Gupta, MD, et al review a case study of a 70-year-old man who presented with a head mass, and the final diagnosis was hepatocellular carcinoma.






Bryant A. Clemons, PharmD, BCOP

Latest:

Optimizing Care for TILs, Cellular Therapy in Melanoma and Solid Tumors

A panel of oncology pharmacists discusses the role of lifileucel in metastatic melanoma and other considerations for using cellular therapy in solid tumors.


Sascha Tuchman, MD

Latest:

Unmet Needs and Future Perspectives in Newly Diagnosed and Relapsed/Refractory MM

The panel shares some unmet needs in the multiple myeloma treatment landscape and exciting developments on the horizon.




Scott Lauer, MD

Latest:

Locally Advanced Gastrointestinal Stromal Tumor in a 33-Year-Old Woman Seeking to Conceive

ABSTRACT Gastrointestinal stromal tumors (GISTs) are rare neoplasms of the gastrointestinal tract. They commonly present with nonspecific symptoms and thus are often discovered incidentally. They are best identified by CT scan and most stain positive for CD117 (C-Kit), CD34, and/or DOG-1. Several risk stratification classification systems have been developed based on tumor size, mitotic rate, location, and perforation. Traditional chemotherapy and radiation therapy have been very ineffective, making surgery the mainstay of treatment. The discovery of mutations associated with these tumors has revolutionized the treatment approach. Imatinib mesylate, a selective tyrosine kinase receptor inhibitor, used as adjuvant or neoadjuvant therapy, has greatly improved the morbidity and mortality associated with GISTs. As the survival of patients has increased with the long-term use of targeted therapies, quality-of-life issues now have become much more relevant and have come to the forefront of care. We present a young woman who was successfully treated for GIST but now faces associated long-term adverse effects of imatinib, including the challenge of preserving fertility and the potential for childbearing.









Annamaria Motta

Latest:

Life Experience of Survivors of Gynecologic Cancers: A Survey Conducted in Italy

A survey was conducted in Italy for survivors of gynecologic cancer regarding quality of life, specifically that of sexual activity after a cancer diagnosis.


Dennis Verducci, APRN

Latest:

Unmet Needs and Future Perspectives in Multiple Myeloma

A panel of experts discuss unmet needs in multiple myeloma and offer perspectives on the future treatment landscape.


Yvonne Efebera, MD

Latest:

Unmet Needs and Future Directions for GPRC5D Bispecific Therapy

Panelists discuss how unmet needs and future directions for GPRC5D bispecific therapy include improving accessibility, managing long-term safety, and exploring combination strategies to enhance treatment efficacy.


Alexandra M. Miller, MD, PhD

Latest:

Addressing Hepatotoxicity in Clinical Practice for IDH-Mutant Gliomas

Panelists discuss how to manage borderline transaminase elevations in a patient benefiting from voracidinib therapy, balancing the risk of mild liver toxicity against continued disease control while investigating potential contributing factors.



Adam Friedman, MD, FAAD

Latest:

Crucial Communication Strategies for Dermatologic AEs of Cancer Therapies

Adam Friedman, MD, FAAD, discusses essential communication strategies for oncologists to address patient fears about dermatologic adverse effects.


Kira MacDougall, MD

Latest:

Oncology Peer Review On-The-Go: The Prognostic Significance of Peripheral Blood Biomarkers in Patients With Advanced Non–Small Cell Lung Cancer Treated With Pembrolizumab: A Clinical Study

Kira MacDougall, MD, and Muhammad Rafay Khan Niazi, MD, spoke with CancerNetwork® about their research into the significance of peripheral blood biomarkers of response to immunotherapy in non–small cell lung cancer published in the journal ONCOLOGY®.


Tania Patricia Hernández-Barragán, MD, MSc

Latest:

The Role of Postmastectomy Radiotherapy in Locally Advanced Breast Cancer After Pathological Complete Response to Neoadjuvant Chemotherapy

Experts examine the case of a previously healthy woman, aged 32 years, presented to the oncology clinic with a 6-month history of left-breast tumor, mastalgia, and swollen axillary nodes.


Timothy Robinson, MD, PhD

Latest:

Radiotherapy/CAR T Combo May be “Great Option” in Relapsed/Refractory DLBCL

No evidence indicates synergistic toxicity when combining radiation with CAR T-cell therapy in this population, according to Timothy Robinson, MD, PhD.


Govindarajan Narayanan, MD

Latest:

Adapting to a Robotic Workstation for Image-Guided Liver Cancer Surgery

Govindarajan Narayanan, MD, speaks to the potential time-saving advantages of using the Epione robot for microwave ablation, cryoablation, and other surgical strategies in patients with liver cancer and other tumors.